How checkpoint inhibitors are changing the treatment paradigm in solid tumors: what advanced practitioners in oncology should know
Release date: July 12, 2016
Expiration date: July 11, 2017
Estimated time of completion: 1 hour
This Activity Includes:
- CE-certified text module
This activity is designed to educate advanced practitioners, oncology nurses, and other healthcare professionals about the fundamental principles of immunotherapy; to expand their knowledge base regarding the advances that checkpoint inhibitors have made in the treatment of melanoma, non–small cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC); to help them better understand, anticipate, and monitor for unique side effects of immunotherapies and to promote best-practice implementation of these agents in clinical practice.
Solid tumors like melanoma, RCC, and lung cancer have historically been difficult to treat with traditional chemotherapy options and non-specific immunotherapies. Advances in immunotherapy, however, have provided new treatment options and are changing the way clinicians and nurses manage these and other cancers. Immune checkpoint inhibitors are emerging as an important new type of treatment for patients with different types of solid tumors. These agents target programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) interactions and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) pathways on regulatory T cells, resulting in an enhancement of immune response and immune-related anti-tumor effects.
This activity will discuss the fundamental principles of immunotherapy; describe recent data that show the advances that checkpoint inhibitors have made in the treatment of melanoma, non–small cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC); help learners to better understand, anticipate, and monitor for unique side effects of immunotherapies and assist them in developing best-practice implementation of these agents in clinical practice.
This activity is intended for advanced practice registered nurses, oncology nurses, and other healthcare providers who manage solid tumors, including melanoma, lung, and renal cell carcinoma.
At the conclusion of this activity, participants should be able to:
- Discuss the role of the immune system in cancer progression and resistance
- Describe the mechanisms of action of checkpoint inhibitors including their impact on the immune system
- Compare differences in efficacy and safety between checkpoint inhibitors and conventional treatments in oncology
- Monitor and manage toxicities associated with immune checkpoint inhibitors
- Provide appropriate care and counsel for patients and their families
|Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®|
Yale University School of Nursing
Oncology Nurse Practitioner
Yale University School of Medicine
New Haven, Connecticut
Nursing Continuing Education
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.10 contact hours is provided by Postgraduate Institute for Medicine.
Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME credit for this activity. During the period 7/12/2016 through 7/11/2017, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v22.214.171.124 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v126.96.36.199 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®||Speakers' Bureau - Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 month
The following AXIS planners and managers Linda Gracie-King, MS; Ronald Viggiani, MD; and Jocelyn Timko, BS hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
MEDIA: Text Article
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly provided by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
Jointly provided by
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
- 1.10 ANCC
- 1.10 Attendance